Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma
Explore comprehensive population pharmacokinetic analyses of belantamab mafodotin, evaluating both monotherapy and combination regimens in…
CertaraAugust 13, 2025
Replacing Traditional TQT Studies with Model-Based Concentration-QTc (C-QTc) Analysis for Cardiovascular Safety in Drug Development
Learn how our experts use concentration-QTc (C-QTc) analysis to replace costly TQT studies, streamline QT…
CertaraAugust 6, 2025
The Medicine Maker: The Biosimulation Generation
The article, The Biosimulation Generation, explores the transformative potential of biosimulation in pharmaceutical R&D as…
Danielle PillsburyJuly 1, 2025
Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning
Due to the highly controlled settings of clinical trials, enrolled subjects may not be fully…
Danielle PillsburyJune 19, 2025
From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara
Discover the Real-World Impact of Model-Based Meta-Analysis. Hear from experts, see case studies to advance…
CertaraJune 18, 2025
What are the most common in vitro drug-drug interaction study gaps?
Certara drug interaction science experts share data and experimental design gaps commonly found in in…
CertaraJune 9, 2025
Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer
The study, published in the Journal of Clinical Pharmacology, evaluates the cardiac safety of fruquintinib,…
CertaraJune 8, 2025
Explore First: How a Stepwise Approach to QTc Studies Reduces Time, Cost, and Regulatory Risk
Learn how a stepwise C-QTc approach can streamline cardiac safety evaluation, reduce costs, and align…
CertaraMay 5, 2025
